Cartesian Therapeutics (RNAC) Return on Sales (2016 - 2025)
Historic Return on Sales for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to 43.18%.
- Cartesian Therapeutics' Return on Sales fell 44200.0% to 43.18% in Q3 2025 from the same period last year, while for Sep 2025 it was 76.75%, marking a year-over-year decrease of 723900.0%. This contributed to the annual value of 1.99% for FY2024, which is 64600.0% up from last year.
- As of Q3 2025, Cartesian Therapeutics' Return on Sales stood at 43.18%, which was down 44200.0% from 67.33% recorded in Q2 2025.
- Cartesian Therapeutics' 5-year Return on Sales high stood at 31.99% for Q4 2024, and its period low was 67.33% during Q2 2025.
- Moreover, its 5-year median value for Return on Sales was 0.73% (2021), whereas its average is 8.9%.
- Its Return on Sales has fluctuated over the past 5 years, first skyrocketed by 557800bps in 2024, then plummeted by -677700bps in 2025.
- Over the past 5 years, Cartesian Therapeutics' Return on Sales (Quarter) stood at 0.41% in 2021, then decreased by -14bps to 0.35% in 2022, then tumbled by -6880bps to 23.79% in 2023, then skyrocketed by 234bps to 31.99% in 2024, then plummeted by -235bps to 43.18% in 2025.
- Its Return on Sales was 43.18% in Q3 2025, compared to 67.33% in Q2 2025 and 18.07% in Q1 2025.